Tecentriq atezolizumab: Additional Phase Ib data

Additional data from 23 evaluable patients with colorectal cancer in an open label, international Phase Ib trial showed that 800 mg

Read the full 212 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE